Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AbCellera and MassBiologics partner for fully human antibodies
September 2016
SHARING OPTIONS:

VANCOUVER, British Columbia—AbCellera Biologics Inc. announced this quarter its third antibody discovery collaboration with MassBiologics of the University of Massachusetts Medical School.
 
This collaboration, funded by the Defense Advanced Research Project Agency (DARPA) under the ADEPT-PROTECT program, focuses on addressing the rapidly growing, unmet global health threat caused by the multidrug-resistant bacteria Klebsiella pneumoniae, which is among the leading causes of hospital-acquired infections worldwide. AbCellera will apply its single-cell antibody discovery platform to identify panels of antibody candidates against Klebsiella pneumoniae directly from human volunteers.
 
“AbCellera’s technology has the throughput, speed and capacity to deeply screen natural human antibody responses to these pathogens,” said Carl Hansen, CEO and co-founder of AbCellera. “We are pleased at the opportunity to expand our collaboration with MassBiologics, and believe this work will further demonstrate the strength of our approach for rapid human antibody discovery, immune profiling and vaccine development.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.